OmicVision Biosciences ApS

Q: What is the CVR number of OmicVision Biosciences ApS?

OmicVision Biosciences ApS is registered with CVR / Virk under CVR 44285584.

Q: How many employees does OmicVision Biosciences ApS have?

OmicVision Biosciences ApS employs 17 people as of the latest annual report.

Q: Who is the CEO of OmicVision Biosciences ApS?

Ishani Tara Ummat is the CEO of OmicVision Biosciences ApS, in role since 2024.

Q: Who is the chairman of OmicVision Biosciences ApS?

Ole Vorm chairs the board of OmicVision Biosciences ApS.

Q: Where is OmicVision Biosciences ApS headquartered?

OmicVision Biosciences ApS's registered address is Ryesgade 113.

APSActiveAdvertising protection

CVR 44285584Ryesgade 113, 2100 København ØResearch and experimental development on natural sciences and engineering· NACE 7210Est. 2023 · 3 years old17 employeeshttps://www.omicvision.com

Overview

OmicVision Biosciences ApS is a Danish APS based in København Ø, operating in the Research and experimental development on natural sciences and engineering sector. Incorporated in 2023, the company has 17 employees and reported a gross profit of DKK 3.6m in its latest annual filing.

Gross profit 2025

3.6M DKK

+133% vs 2024

EBITDA margin (of gross profit)

−123.6 %

−26% vs 2024

Net profit 2025

-4.4M DKK

-47% vs 2024

Key ratios

See full ratios →

1.0 %

Very weak

Among the 20% lowest rated companies in the industry

20242025

4.7×

Strong

Among the 30% highest rated companies in the industry

20242025

-35.8 %

Very weak

Among the 20% lowest rated companies in the industry

20242025

EBITDA — year on year

DKK thousands

Key figures

Annual report 2025

Gross profit	3.6M DKK	+133%
EBITDA	-4.4M DKK	-26%
Net profit	-4.4M DKK	-47%
Total assets	12.3M DKK	+125%
Equity	0.1M DKK	-97%
Employees	17	—

Contact

Address

Ryesgade 113, 2100 København Ø

Phone

+45 3184 9498

iummat@omicvision.com

Website

https://www.omicvision.com

Advertising protection

Active — opted out of marketing use

Risika for professionals

Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.

Visit risika.com

Financial development

In its most recent annual report (2025), OmicVision Biosciences ApS reported a gross profit of DKK 3.6m, an increase of 133% on the year before. The figures on this page draw on 2 annual filings covering 2024 to 2025. The bottom line showed a net loss of DKK 4.4m, and the EBITDA margin stood at -123.6%.

At the end of 2025, equity financed 1% of the balance sheet, and current assets covered short-term debt 4.7 times. OmicVision Biosciences ApS is one of 2 companies registered under Research and experimental development on natural sciences and engineering in Denmark.

Financials

Gross profit

DKK thousands

EBITDA

DKK thousands

Income statement

DKK thousands

Item	2025	2024
Gross profit	3,582	1,538
Staff expenses	-8,011	-4,708
EBITDA	-4,429	-3,523
Depreciation & amort.	-38	-21
EBIT	-4,467	-3,544
Net financials	51	113
Profit before tax	-4,416	-3,431
Tax	-0	-424
Net profit	-4,416	-3,007

Get a credit rating – not just the numbers

Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.

See the credit rating

Balance sheet

DKK thousands

Item	2025	2024
Total assets	12,342	5,486
Equity	117	4,533
Long-term debt	9,654	0
Short-term debt	2,571	953
Total debt	12,225	953

Financial ratios

5-year trend

EBITDA margin (of gross profit)

-123.6 %

20242025

Equity ratio

1.0 %

Very weak

Among the 20% lowest rated companies in the industry

20242025

Return on equity

<−999 %

Very weak

Among the 10% lowest rated companies in the industry

20242025

Net profit margin (of gross profit)

-123.3 %

20242025

Asset turnover (of gross profit)

0.29×

20242025

Debt / equity

104.15×

Very weak

Among the 10% lowest rated companies in the industry

20242025

Sector performance

23 of 28 ratios graded

28 financial ratios from the latest filing, each graded against companies in the same industry.

Profitability

Return on equity (ROE)Very weak

Among the 10% lowest rated companies in the industry

Net profit as a percentage of equity — the return the owners earned on their invested capital this year.

Return on assets (ROA)Very weak

Among the 20% lowest rated companies in the industry

Net profit as a percentage of total assets — the return generated on the capital employed.

Return on net assets (RONA)Very weak

Among the 10% lowest rated companies in the industry

Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.

Basic earning power (BEP)Very weak

Among the 20% lowest rated companies in the industry

EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.

Capacity ratioVery weak

Among the 20% lowest rated companies in the industry

Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.

Gross marginNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.

Operating marginNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.

Net profit marginNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

The profit for the year as a share of revenue — the company's ability to turn revenue into profit.

Liquidity

Current ratioStrong

Among the 30% highest rated companies in the industry

Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.

Quick ratioStrong

Among the 30% highest rated companies in the industry

Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.

Cash ratioStrong

Among the 30% highest rated companies in the industry

Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.

Current assets to equityVery weak

Among the 10% lowest rated companies in the industry

Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.

Fixed assets to long-term capitalAverage

Around the average of companies in the same industry

Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.

Cash conversion ratioAverage

Around the average of companies in the same industry

Cash flow relative to profit — the ability to convert reported profits into accessible cash.

Debt & solvency

Solidity ratioVery weak

Among the 20% lowest rated companies in the industry

Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.

Debt ratioVery weak

Among the 20% lowest rated companies in the industry

Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.

Debt to equityVery weak

Among the 10% lowest rated companies in the industry

Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.

Liabilities to equityVery weak

Among the 10% lowest rated companies in the industry

Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.

Income to debtVery weak

Among the 20% lowest rated companies in the industry

Profit relative to debt — the ability to create earnings while operating with debt.

EBITDA to debtVery weak

Among the 20% lowest rated companies in the industry

EBITDA relative to debt — how much operating earnings are available to service the debt.

Interest coverageVery weak

Among the 10% lowest rated companies in the industry

The ability to pay the interest on the company's debt out of its earnings.

Interest rate on debtAverage

Around the average of companies in the same industry

Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.

Interest marginVery weak

Among the 20% lowest rated companies in the industry

The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.

Efficiency & development

Equity to contributed capitalWeak

Among the 40% lowest rated companies in the industry

Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.

One-year change in equityVery weak

Among the 10% lowest rated companies in the industry

The size of this year's increase or decrease in the company's equity.

One-year change in debtVery weak

Among the 10% lowest rated companies in the industry

The size of this year's increase or decrease in the company's debt.

Asset turnoverNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Revenue relative to total assets — the ability to generate revenue from the asset base.

Inventory turnoverNot rated

Cannot be graded — the figures this ratio builds on are not available in the latest filing.

Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.

Annual reports & filings

Annual report 2025
Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
View PDF
Annual report 2024
Filed via CVR / Virk · Period 2023-09-01 – 2024-12-31
View PDF

People & ownership

Management

Actively employed in the business

Name	Role	Member since
Current (3)
MT Maximilian Thomas Dr Strauss Management	Management	2023
AM Andreas Mund Management	Management	2023
IT Ishani Tara Ummat Chief Executive Officer	Chief Executive Officer	2024

Board of directors

Non-executive oversight

Name	Role	Member since
Current (3)
MT Maximilian Thomas Dr Strauss Board of Directors	Board of Directors	2023
AM Andreas Mund Board of Directors	Board of Directors	2023
OV Ole Vorm Chairman	Chairman	2023

Shareholders

Active legal owners

Shareholder	Type	Ownership	Votes	Registered
VOMA HOLDING A/S	Company	33.33–49.99%	33.33–49.99%	2024
AM Tech Ventures ApS	Company	15–19.99%	15–19.99%	2024
MS Ventures ApS	Company	15–19.99%	15–19.99%	2024
Ummat Ventures ApS	Company	10–14.99%	10–14.99%	2024

Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.

One in three Danish companies experiences fraud

Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.

See the fraud module

Related companies

Company hierarchy

AM Tech Ventures ApS15%

MS Ventures ApS15%

Ummat Ventures ApS10%

Voma Holding A/S33.33%

OmicVision Biosciences ApS (this company)

Board network connections

Board members of OmicVision Biosciences ApS also hold positions in 12 other companies.

Person	Role here	Other companies
Ole Vorm	Chairman	9 companiesMany roles
Maximilian Thomas Dr Strauss	Management	1 company
Andreas Mund	Management	1 company
Ishani Tara Ummat	Chief Executive Officer	1 company

Frequently asked questions

What is the CVR number of OmicVision Biosciences ApS?

OmicVision Biosciences ApS is registered with CVR / Virk under CVR 44285584.

What is the gross profit of OmicVision Biosciences ApS?

OmicVision Biosciences ApS reported a gross profit of DKK 3.6m in 2025.

How many employees does OmicVision Biosciences ApS have?

OmicVision Biosciences ApS employs 17 people as of the latest annual report.

Who is the CEO of OmicVision Biosciences ApS?

Ishani Tara Ummat is the CEO of OmicVision Biosciences ApS, in role since 2024.

Who is the chairman of OmicVision Biosciences ApS?

Ole Vorm chairs the board of OmicVision Biosciences ApS.

Where is OmicVision Biosciences ApS headquartered?

OmicVision Biosciences ApS's registered address is Ryesgade 113.